Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | KarMMa: Idecabtagene vicleucel for R/R MM

Nikhil Munshi • 1 Jun 2020
ASCO 2020
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa

Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, updates us on results from the KarMMa study (NCT03361748), investigating idecabtagene vicleucel, a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nikhil Munshi

1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023
1:05
Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi • 11 Dec 2023
2:42
Immunotherapeutic approaches to overcoming drug resistance in venetoclax-exposed patients with MM
Nikhil Munshi • 11 Dec 2023
2:02
Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals